Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07072234 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
A Phase 1 study of Clear Cell Carcinoma and Phase 1, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07072234 is a Phase 1 study of Clear Cell Carcinoma and Phase 1 that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, below the 268-participant average among 3 other Clear Cell Carcinoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07072234, a Phase 1 study of Clear Cell Carcinoma and Phase 1, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Dexamethasone
- DRUG Lymphodepleting chemotherapy
- DRUG Cyclophosphamate
- DRUG TGFBR-2 KO CD70 CAR NK
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-25 |
| Est. Completion | 2030-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07072234
The ClinicalTrials.gov registry entry for NCT07072234 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 268-participant average among 3 other Clear Cell Carcinoma trials with a reported enrollment target (89% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Clear Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT07072234 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07072234 about?
NCT07072234 is a clinical study titled "Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma". Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.
What is the current status of trial NCT07072234?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-09-25. Estimated completion is 2030-02-01.
What conditions does trial NCT07072234 study?
This clinical trial studies the following conditions: Clear Cell Carcinoma, Phase 1, Growth Factor.
What interventions are being tested in trial NCT07072234?
The interventions under investigation include: Fludarabine (DRUG), Dexamethasone (DRUG), Lymphodepleting chemotherapy (DRUG), Cyclophosphamate (DRUG), TGFBR-2 KO CD70 CAR NK (DRUG).
Who is sponsoring clinical trial NCT07072234?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07072234 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
RECRUITING · NA
-
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Nivolumab in Selected Uterine Cancer Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.